News and Media
News and Media
Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting
February 13, 2019
Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor
January 3, 2019
BioAlliance Pharma provides updates on its major achievements and reports 2013 consolidated financial results
July 27, 2014
BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions
April 8, 2014
Publication of the 2013 Registration Document
April 8, 2014
BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea
April 2, 2014
BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig®
April 1, 2014
BioAlliance Pharma collaborates with Penn Pharma on the industrial development of Validive®
March 31, 2014
Sitavig® Licensing Strategy: Execution of licensing agreement with Innocutis for North America and Positive opinion from French and German Health Authorities for Marketing Authorization
March 19, 2014
Strengthening and extension of the industrial protection of Livatag® until 2031 – First delivery of a new European patent
February 18, 2014
BioAlliance Pharma’s partner, Sosei, announces a partnership with FUJIFILM Pharma for commercialization rights for Loramyc® in Japan
February 4, 2014
FDA grants Validive® (clonidine Lauriad®) with a Fast Track Designation for the prevention and treatment of oral mucositis induced by anticancer treatments
January 23, 2014
Quarterly information as of September 30, 2013
November 14, 2013
Key milestones and consolidated accounts First semester 2013
September 19, 2013
Bioalliance Pharma updates on major achievements of 2012 and publishes its 2012 consolidated financial statements and income for Q1 2013
April 15, 2013
[wd_hustle id=”2″ type=”embedded”/]
